Eisai and Biogen’s marketing application for Alzheimer’s disease therapy Leqembi will face an independent advisory committee convened by the EMA before a decision is made
One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson's disease – AbbVie – is ducking out of the challenge.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh